Ocuphire Pharma, Inc. (OCUP) Stock Analysis

Ocuphire Pharma, Inc. (OCUP) Healthcare & Pipeline Overview

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company specializing in ophthalmic therapies, with a focus on refractive and retinal disorders. Their lead candidate, Nyxol, targets dim light disturbances, mydriasis, and presbyopia. The company is also developing oral tablets for retinal vascular diseases, positioning them in a competitive biotechnology landscape.

What Is the Investment Thesis for OCUP?

Ocuphire Pharma, Inc. presents a notable research candidate due to its promising lead product candidate, Nyxol, and its pipeline of therapies targeting significant unmet needs in ophthalmology. The successful completion of Phase III trials for Nyxol in dim light disturbances could lead to rapid market adoption, given the lack of effective treatments currently available. Positive results from the Phase 2b trial for mydriasis and the VEGA-1 trial for presbyopia further enhance Nyxol's potential. The development of APX3330, targeting retinal vascular diseases, diversifies the company's portfolio and addresses a large and growing market. However, the company's negative profit margin of -349.3% and reliance on clinical trial outcomes pose significant risks. The company's market capitalization is $0.03B as of 2026-03-17. The P/E ratio is -61.18.

Based on FMP financials and quantitative analysis

OCUP Key Highlights

Nyxol eye drops are in Phase III clinical trials for dim light or night vision disturbances, addressing a significant unmet need.

• Nyxol is also in Phase 2b clinical trials for pharmacologically induced mydriasis, offering a potential solution for managing pupil dilation.
• The company's gross margin stands at 57.4%, indicating strong potential profitability upon successful commercialization.
• APX3330, an oral tablet, targets retinal and choroidal vascular diseases, expanding the company's therapeutic focus.
• The company's market capitalization is $0.03B as of 2026-03-17, reflecting its current stage of development.

Who Are OCUP's Competitors?

OCUP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OCUP's Key Strengths?

Promising lead product candidate, Nyxol, in Phase III trials.

• Pipeline of therapies targeting significant unmet needs in ophthalmology.
• Experienced management team with expertise in drug development.
• Proprietary formulations and drug delivery technologies.

What Are OCUP's Weaknesses?

Clinical-stage company with no currently marketed products.

• High reliance on clinical trial outcomes and regulatory approvals.
• Negative profit margin and limited financial resources.
• Small number of employees (14).

What Could Drive OCUP Stock Higher?

Completion of Phase III clinical trials for Nyxol in dim light disturbances.

• Results from Phase 2b clinical trials for Nyxol in pharmacologically induced mydriasis.
• Regulatory submissions for Nyxol to the FDA.
• Development of APX3330 for diabetic retinopathy and diabetic macular edema.
• Advancement of second-generation preclinical product candidates, APX2009 and APX2014.

What Are the Key Risks for OCUP?

Financial-distress signal — its Altman Z-Score of -3.59 sits in the distress zone (elevated bankruptcy risk).

• Failure to achieve positive clinical trial results for Nyxol or APX3330.
• Regulatory delays or rejection of their product candidates by the FDA.
• Competition from other biopharmaceutical companies developing ophthalmic therapies.
• Patent challenges or loss of exclusivity for their key products.
• The company's negative profit margin and limited financial resources.

What Are the Growth Opportunities for OCUP?

• Growth opportunity 1: Successful completion and FDA approval of Nyxol for dim light disturbances represents a significant growth opportunity. The market for night vision disturbance treatments is underserved, and Nyxol's unique mechanism of action could capture a substantial share. The timeline for potential approval is dependent on the Phase III trial results and subsequent regulatory review, but market launch could occur within 2-3 years post-positive data. This indication addresses a market size estimated at hundreds of millions of dollars annually.
• Growth opportunity 2: Expansion of Nyxol's label to include pharmacologically induced mydriasis offers another avenue for growth. The ability to quickly reverse mydriasis after eye exams would be highly valued by ophthalmologists and patients. Positive Phase 2b trial results could pave the way for Phase III trials and potential market launch within 3-4 years. The market for mydriasis reversal agents is estimated to be significant, driven by the frequency of eye exams requiring pupil dilation.
• Growth opportunity 3: The development and commercialization of APX3330 for diabetic retinopathy and diabetic macular edema represents a major growth opportunity. These retinal vascular diseases affect millions worldwide, and effective oral treatments are highly sought after. Successful clinical trials and regulatory approval could lead to significant revenue generation within 4-5 years. The market for diabetic retinopathy and macular edema treatments is multi-billion dollar.
• Growth opportunity 4: Advancing the second-generation preclinical product candidates, APX2009 and APX2014, provides a long-term growth opportunity. These analogs of APX3330 could offer improved efficacy or safety profiles, further strengthening the company's pipeline. While still in the early stages of development, these candidates represent a commitment to innovation and could yield valuable assets in the future. The timeline for these products is 5+ years.
• Growth opportunity 5: Strategic partnerships and collaborations with larger pharmaceutical companies could accelerate the development and commercialization of Ocuphire's products. Partnering could provide access to additional funding, expertise, and distribution channels. This could expedite the timeline for bringing new therapies to market and maximize their commercial potential. The timing and nature of potential partnerships are uncertain, but they represent a valuable growth opportunity.

What Are OCUP's Competitive Advantages?

• Patent protection for their lead product candidate, Nyxol.
• Proprietary formulations and drug delivery technologies.
• Clinical data demonstrating the efficacy and safety of their therapies.
• Expertise in ophthalmic drug development.

What Does OCUP Do?

Ocuphire Pharma, Inc., established to address unmet needs in ophthalmic care, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for refractive and retinal eye disorders. The company's primary focus is on advancing treatments that can significantly improve vision and quality of life for patients. Their lead product candidate, Nyxol eye drops, represents a significant advancement in the treatment of several eye conditions. Nyxol is a once-daily, preservative-free formulation of phentolamine mesylate. It is currently in Phase III clinical trials for the treatment of dim light or night vision disturbances, addressing a critical need for individuals who struggle with vision in low-light conditions. Additionally, Nyxol is in Phase 2b clinical trials for pharmacologically induced mydriasis, offering a potential solution to manage pupil dilation after eye exams. The Phase 2 VEGA-1 trial for presbyopia has been completed, showing promising results. Beyond Nyxol, Ocuphire is also developing APX3330, an oral tablet designed to target pathways relevant to retinal and choroidal vascular diseases. This twice-a-day treatment aims to address conditions such as diabetic retinopathy and diabetic macular edema, which are major causes of vision loss worldwide. Furthermore, the company is working on APX2009 and APX2014, second-generation preclinical product candidates and analogs of APX3330, demonstrating a commitment to continuous innovation in retinal disease treatment. Headquartered in Farmington Hills, Michigan, Ocuphire Pharma, Inc. is striving to establish itself as a key player in the ophthalmic biopharmaceutical space.

What Products and Services Does OCUP Offer?

• Develop therapies for refractive eye disorders.
• Develop therapies for retinal eye disorders.
• Focus on unmet needs in ophthalmic care.
• Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
• Seek regulatory approval for their therapies.
• Commercialize approved therapies to improve vision and quality of life for patients.

How Does OCUP Make Money?

• Develop and license ophthalmic pharmaceutical products.
• Conduct clinical trials to prove efficacy and safety.
• Seek regulatory approvals from agencies like the FDA.
• Potentially partner with larger pharmaceutical companies for commercialization.

What Industry Does OCUP Operate In?

Ocuphire Pharma, Inc. operates within the competitive biotechnology industry, specifically focusing on ophthalmic therapies. The market for eye disorder treatments is substantial and growing, driven by an aging population and increasing prevalence of conditions like diabetic retinopathy and presbyopia. The company competes with other biopharmaceutical firms such as ALLK, ANGN, FRLN, GRCE, and LIANY, as well as larger pharmaceutical companies with ophthalmic divisions. Success in this industry requires navigating complex regulatory pathways, securing patent protection, and demonstrating clinical efficacy.

Who Are OCUP's Key Customers?

• Patients with dim light or night vision disturbances.
• Patients with pharmacologically induced mydriasis.
• Patients with diabetic retinopathy.
• Ophthalmologists and eye care professionals.

The most recent 12 insider filings for Ocuphire Pharma, Inc. break down as 0 sales and 12 purchases. On net that is roughly 458K shares acquired (about $363K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Ocuphire Pharma, Inc.

Revenue for Ocuphire Pharma, Inc. came in at $0 during Q1 2026, a 100.0% contraction versus the preceding quarter. The company recorded a net loss of $65.5M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, OCUP averaged $-0.12 in diluted EPS.

OCUP Valuation & Market Position

With a $31.7M market cap, Ocuphire Pharma, Inc. sits in the micro-cap segment of the market.

Key Financial Metrics

Its free cash flow yield is -11.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.

Ocuphire Pharma, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.59 places it in the distress zone, a signal of elevated financial risk.

Ocuphire Pharma, Inc. has beaten Wall Street's EPS estimate in 3 of its last 6 reported quarters — more hits than misses. Reported results have landed about 30.4% above estimates on average.

Wall Street analysts project Ocuphire Pharma, Inc. revenue of about $35.8M for fiscal 2026, with EPS near $-0.30. The estimate reflects 4 contributing analysts.

Company Profile

Ocuphire Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Farmington Hills, US. The company is led by CEO George Magrath. OCUP has traded publicly since 2005.

OCUP Financials

OCUP Latest News

No recent news available for OCUP.

What Investors Ask About Ocuphire Pharma, Inc. (OCUP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources